Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease.

Botulinum neurotoxins, responsible for the neuroparalytic syndrome botulism, are the deadliest of known biological toxins. The work described in this study was based on a three-zone pharmacophore model for botulinum neurotoxin serotype A light chain inhibition. Specifically, the pharmacophore defined a separation between the overlaps of several different, non-zinc(II)-coordinating small molecule chemotypes, enabling the design and synthesis of a new structural hybrid possessing a Ki=600 nM (+/-100 nM).
AuthorsJ C Burnett, C Wang, J E Nuss, T L Nguyen, A R Hermone, J J Schmidt, R Gussio, P Wipf, S Bavari
JournalBioorganic & medicinal chemistry letters (Bioorg Med Chem Lett) Vol. 19 Issue 19 Pg. 5811-3 (Oct 01 2009) ISSN: 1464-3405 [Electronic] England
PMID19703771 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Neurotoxins
  • Protease Inhibitors
  • Botulinum Toxins, Type A
  • Zinc
  • Botulinum Toxins, Type A (antagonists & inhibitors, metabolism)
  • Drug Design
  • Neurotoxins (antagonists & inhibitors, metabolism)
  • Protease Inhibitors (chemical synthesis, chemistry, pharmacology)
  • Stereoisomerism
  • Structure-Activity Relationship
  • Zinc (chemistry)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: